Momentum around women's health treatments is building, and Lipocine Inc. (LPCN) has stepped into the spotlight with its oral brexanolone candidate, LPCN 1154, now advancing through a pivotal Phase 3 program for postpartum depression (PPD). With key clinical milestones approaching in 2026, Lipocine's development efforts highlight its broader commitment to patient-focused innovation in central nervous system disorders.
Shares of the company recently mirrored this progress, closing at $4.20 with a 14.44% gain for the day and edging slightly higher to $4.23 in after-hours trading.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com